Manil Subesinghe
Research Subjects
Manil Subesinghe has a total of 260 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Frederick Scarsbrook
Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
10 shared publications - Gary James R. Cook
School of Biomedical Engineering and Imaging Sciences, King’s College London, London, UK
6 shared publications - Fergus Vincent Gleeson
Mayo Clinic, Rochester, United States of America
4 shared publications - Robin J. D. Prestwich
Department of Clinical Oncology, Leeds Teaching Hospitals NHS Trust, Leeds Cancer Centre, Leeds, England, LS9 7TF, United Kingdom of Great Britain and Northern Ireland
4 shared publications - Fahmid U. Chowdhury
Department of Clinical Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK
3 shared publications Kevin M. Bradley
PETIC, Wales Research and Diagnostic PET Imaging Centre, Cardiff, United Kingdom
3 shared publications
Latest Publications
- 11 April 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (9) , 856-858
Epicardial Metastases Causing Coronary Artery Compression and Myocardial Infarction on [18F]FDG PET-CT
A 64-year-old woman with metastatic lung adenocarcinoma on immune checkpoint inhibitor (ICI) therapy suffered an acute coronary syndrome and underwent percutaneous coronary intervention (PCI). Despite PCI and anti-anginal therapy, she continued to experience angina. Cardiac magnetic resonance imaging (CMR) suggested a diagnosis of ICI myocarditis. However, refractory angina and non-resolving changes on CMR despite high-dose steroids prompted further evaluation with [18F]FDG PET-CT; this yielded a final diagnosis of epicardial metastatic coronary artery compression with myocardial infarction. This case demonstrates the incremental diagnostic value of multimodality imaging in cardio-oncology.
- 11 April 2025
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 50 (9) , 856-858
Epicardial Metastases Causing Coronary Artery Compression and Myocardial Infarction on [18F]FDG PET-CT
A 64-year-old woman with metastatic lung adenocarcinoma on immune checkpoint inhibitor (ICI) therapy suffered an acute coronary syndrome and underwent percutaneous coronary intervention (PCI). Despite PCI and anti-anginal therapy, she continued to experience angina. Cardiac magnetic resonance imaging (CMR) suggested a diagnosis of ICI myocarditis. However, refractory angina and non-resolving changes on CMR despite high-dose steroids prompted further evaluation with [18F]FDG PET-CT; this yielded a final diagnosis of epicardial metastatic coronary artery compression with myocardial infarction. This case demonstrates the incremental diagnostic value of multimodality imaging in cardio-oncology.
- Open Access
- 24 May 2024
- Published by Elsevier in Clinical Radiology
- Vol. 79 (9) , 639-656
Prostate specific membrane antigen (PSMA) avid nonprostatic benign and malignant disease: a pictorial review
- 24 May 2024
- Published by Elsevier in Clinical Radiology
- Vol. 79 (9) , 639-656
Open AccessProstate specific membrane antigen (PSMA) avid nonprostatic benign and malignant disease: a pictorial review
- Open Access
- 9 December 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (1) , rkae002
Treatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope
The last British Society for Rheumatology (BSR) guideline on PMR was published in 2009. The guideline needs to be updated to provide a summary of the current evidence for pharmacological and non-pharmacological management of adults with PMR. This guideline is aimed at healthcare professionals in the UK who directly care for people with PMR, including general practitioners, rheumatologists, nurses, physiotherapists, occupational therapists, pharmacists, psychologists and other health professionals. It will also be relevant to people living with PMR and organisations that support them in the public and third sector, including charities and informal patient support groups. This guideline will be developed using the methods and processes outlined in the BSR Guidelines Protocol. Here we provide a brief summary of the scope of the guideline update in development.
- 9 December 2023
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (1) , rkae002
Open AccessTreatment of polymyalgia rheumatica: British Society for Rheumatology guideline scope
The last British Society for Rheumatology (BSR) guideline on PMR was published in 2009. The guideline needs to be updated to provide a summary of the current evidence for pharmacological and non-pharmacological management of adults with PMR. This guideline is aimed at healthcare professionals in the UK who directly care for people with PMR, including general practitioners, rheumatologists, nurses, physiotherapists, occupational therapists, pharmacists, psychologists and other health professionals. It will also be relevant to people living with PMR and organisations that support them in the public and third sector, including charities and informal patient support groups. This guideline will be developed using the methods and processes outlined in the BSR Guidelines Protocol. Here we provide a brief summary of the scope of the guideline update in development.
- Open Access
- 25 November 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (2) , 173-174
18F-FDG PET/CT Imaging of Idiopathic Granulomatous Mastitis
A 43-year-old woman, who presented with a suspected left breast abscess, underwent serial ultrasounds, which demonstrated inflammatory changes that were nonresponsive to antibiotics and which spread to the contralateral breast. 18F-FDG PET/CT demonstrated diffuse heterogeneous intense FDG uptake in both breasts with reactive axillary nodes. Breast biopsy confirmed granulomatous inflammation, and overall findings were consistent with idiopathic granulomatous mastitis. In the absence of histological analysis, idiopathic granulomatous mastitis is an important differential diagnosis to consider for bilateral abnormal breast uptake, and early recognition can facilitate prompt commencement of treatment.
- 25 November 2023
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 49 (2) , 173-174
Open Access18F-FDG PET/CT Imaging of Idiopathic Granulomatous Mastitis
A 43-year-old woman, who presented with a suspected left breast abscess, underwent serial ultrasounds, which demonstrated inflammatory changes that were nonresponsive to antibiotics and which spread to the contralateral breast. 18F-FDG PET/CT demonstrated diffuse heterogeneous intense FDG uptake in both breasts with reactive axillary nodes. Breast biopsy confirmed granulomatous inflammation, and overall findings were consistent with idiopathic granulomatous mastitis. In the absence of histological analysis, idiopathic granulomatous mastitis is an important differential diagnosis to consider for bilateral abnormal breast uptake, and early recognition can facilitate prompt commencement of treatment.
- Open Access
- 1 November 2022
- Published by Elsevier in Clinical Radiology
- Vol. 78 (2) , e89-e98
The frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma
- 1 November 2022
- Published by Elsevier in Clinical Radiology
- Vol. 78 (2) , e89-e98
Open AccessThe frequency of change in five-point scale score with a Bayesian penalised likelihood PET reconstruction algorithm on interim FDG PET-CT and its potential implications for therapy decisions in Hodgkin's lymphoma
- 1 August 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 304 (2) , 246-264
18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
This review highlights the current applications and future potential of molecular imaging techniques as companion diagnostics during anti-cancer immunotherapy to stratify patients, monitor molecula... Immunotherapy has transformed the treatment landscape of many cancers, with durable responses in disease previously associated with a poor prognosis. Patient selection remains a challenge, with pre...
- 1 August 2022
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 304 (2) , 246-264
18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
This review highlights the current applications and future potential of molecular imaging techniques as companion diagnostics during anti-cancer immunotherapy to stratify patients, monitor molecula... Immunotherapy has transformed the treatment landscape of many cancers, with durable responses in disease previously associated with a poor prognosis. Patient selection remains a challenge, with pre...
- Open Access
- 31 August 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (5) , 1769-1782
2-deoxy-2[18F]fluoro-D-glucose positron emission tomography–computed tomography in rheumatological diseases
2-deoxy-2[18F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a number of inflammatory cells. Exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wide range of infective and inflammatory diseases. Rheumatological diseases can affect multiple sites within the musculoskeletal system alongside multi-organ extra-articular disease manifestations. Inflammation is central to these diseases, making FDG PET-CT a logical choice. In this review article we describe the various applications of FDG PET-CT in rheumatological diseases using illustrative examples to highlight the beneficial role of FDG PET-CT in each case.
- 31 August 2021
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (5) , 1769-1782
Open Access2-deoxy-2[18F]fluoro-D-glucose positron emission tomography–computed tomography in rheumatological diseases
2-deoxy-2[18F]fluoro-D-glucose (FDG) PET-CT has revolutionized oncological imaging. The cellular processes that make cancer cells visible on FDG PET-CT also occur in a number of inflammatory cells. Exploiting this phenomenon has led to a growth of evidence supporting the use of FDG PET-CT in a wide range of infective and inflammatory diseases. Rheumatological diseases can affect multiple sites within the musculoskeletal system alongside multi-organ extra-articular disease manifestations. Inflammation is central to these diseases, making FDG PET-CT a logical choice. In this review article we describe the various applications of FDG PET-CT in rheumatological diseases using illustrative examples to highlight the beneficial role of FDG PET-CT in each case.
- Open Access
- 29 April 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1130) , 20211079
A case–control evaluation of pulmonary and extrapulmonary findings of incidental asymptomatic COVID-19 infection on FDG PET-CT
Objectives: To describe the findings of incidental asymptomatic COVID-19 infection on FDG PET-CT using a case–control design. Methods: Incidental pulmonary findings suspicious of asymptomatic COVID-19 infection on FDG PET-CT were classified as a confirmed (positive RT-PCR test) or suspected case (no/negative RT-PCR test). Control cases were identified using a 4:1 control:case ratio. Pulmonary findings were re-categorised by two reporters using the BSTI classification. SUV metrics in ground glass opacification (GGO)/consolidation (where present), background lung, intrathoracic nodes, liver, spleen and bone marrow were measured. Results: 7/9 confirmed and 11/15 suspected cases (COVID-19 group) were re-categorised as BSTI 1 (classic/probable COVID-19) or BSTI 2 (indeterminate COVID-19); 0/96 control cases were categorised as BSTI 1. Agreement between two reporters using the BSTI classification was almost perfect (weighted κ = 0.94). SUVmax GGO/consolidation (5.1 vs 2.2; p < 0.0001) and target-to-background ratio, normalised to liver SUVmean (2.4 vs 1.0; p < 0.0001) were higher in the BSTI 1 & 2 group vs BSTI 3 (non-COVID-19) cases. SUVmax GGO/consolidation discriminated between the BSTI 1 & 2 group vs BSTI 3 (non-COVID-19) cases with high accuracy (AUC = 0.93). SUV metrics were higher (p < 0.05) in the COVID-19 group vs control cases in the lungs, intrathoracic nodes and spleen. Conclusion: Asymptomatic COVID-19 infection on FDG PET-CT is characterised by bilateral areas of FDG avid (intensity > x2 liver SUVmean) GGO/consolidation and can be identified with high interobserver agreement using the BSTI classification. There is generalised background inflammation within the lungs, intrathoracic nodes and spleen. Advances in knowledge: Incidental asymptomatic COVID-19 infection on FDG PET-CT, characterised by bilateral areas of ground glass opacification and consolidation, can be identified with high reproducibility using the BSTI classification. The intensity of associated FDG uptake (>x2 liver SUVmean) provides high discriminative ability in differentiating such cases from pulmonary findings in a non-COVID-19 pattern. Asymptomatic COVID-19 infection causes a generalised background inflammation within the mid-lower zones of the lungs, hilar and central mediastinal nodal stations, and spleen on FDG PET-CT.
- 29 April 2021
- Published by Oxford University Press (OUP) in British Journal of Radiology
- Vol. 95 (1130) , 20211079
Open AccessA case–control evaluation of pulmonary and extrapulmonary findings of incidental asymptomatic COVID-19 infection on FDG PET-CT
Objectives: To describe the findings of incidental asymptomatic COVID-19 infection on FDG PET-CT using a case–control design. Methods: Incidental pulmonary findings suspicious of asymptomatic COVID-19 infection on FDG PET-CT were classified as a confirmed (positive RT-PCR test) or suspected case (no/negative RT-PCR test). Control cases were identified using a 4:1 control:case ratio. Pulmonary findings were re-categorised by two reporters using the BSTI classification. SUV metrics in ground glass opacification (GGO)/consolidation (where present), background lung, intrathoracic nodes, liver, spleen and bone marrow were measured. Results: 7/9 confirmed and 11/15 suspected cases (COVID-19 group) were re-categorised as BSTI 1 (classic/probable COVID-19) or BSTI 2 (indeterminate COVID-19); 0/96 control cases were categorised as BSTI 1. Agreement between two reporters using the BSTI classification was almost perfect (weighted κ = 0.94). SUVmax GGO/consolidation (5.1 vs 2.2; p < 0.0001) and target-to-background ratio, normalised to liver SUVmean (2.4 vs 1.0; p < 0.0001) were higher in the BSTI 1 & 2 group vs BSTI 3 (non-COVID-19) cases. SUVmax GGO/consolidation discriminated between the BSTI 1 & 2 group vs BSTI 3 (non-COVID-19) cases with high accuracy (AUC = 0.93). SUV metrics were higher (p < 0.05) in the COVID-19 group vs control cases in the lungs, intrathoracic nodes and spleen. Conclusion: Asymptomatic COVID-19 infection on FDG PET-CT is characterised by bilateral areas of FDG avid (intensity > x2 liver SUVmean) GGO/consolidation and can be identified with high interobserver agreement using the BSTI classification. There is generalised background inflammation within the lungs, intrathoracic nodes and spleen. Advances in knowledge: Incidental asymptomatic COVID-19 infection on FDG PET-CT, characterised by bilateral areas of ground glass opacification and consolidation, can be identified with high reproducibility using the BSTI classification. The intensity of associated FDG uptake (>x2 liver SUVmean) provides high discriminative ability in differentiating such cases from pulmonary findings in a non-COVID-19 pattern. Asymptomatic COVID-19 infection causes a generalised background inflammation within the mid-lower zones of the lungs, hilar and central mediastinal nodal stations, and spleen on FDG PET-CT.
- Open Access
- 1 March 2021
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 51 (2) , 143-156
Artificial Intelligence for the Characterization of Pulmonary Nodules, Lung Tumors and Mediastinal Nodes on PET/CT
- 1 March 2021
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 51 (2) , 143-156
Open AccessArtificial Intelligence for the Characterization of Pulmonary Nodules, Lung Tumors and Mediastinal Nodes on PET/CT
- 1 November 2020
- Published by Elsevier in Clinical Radiology
- Vol. 75 (11) , 878.e21-878.e28
Multi-observer concordance and accuracy of the British Thoracic Society scale and other visual assessment qualitative criteria for solid pulmonary nodule assessment using FDG PET-CT
- 1 November 2020
- Published by Elsevier in Clinical Radiology
- Vol. 75 (11) , 878.e21-878.e28
Multi-observer concordance and accuracy of the British Thoracic Society scale and other visual assessment qualitative criteria for solid pulmonary nodule assessment using FDG PET-CT